Suppr超能文献

胸苷激酶作为晚期乳腺癌化疗反应的预测指标。

Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer.

作者信息

Zhang H J, Kennedy B J, Kiang D T

出版信息

Breast Cancer Res Treat. 1984;4(3):221-5. doi: 10.1007/BF01806488.

Abstract

Cytosols from breast cancers were measured for estrogen receptor (ER) and thymidine kinase (TK) activity. There was no correlation between ER and TK in 137 primary breast cancers studied. The results of TK from 57 metastatic breast cancers were correlated with the response or failure to subsequent hormonal therapy or chemotherapy. TK did not predict the responses to hormonal therapy in 12 patients. Of the 45 patients treated with chemotherapies, 13 of 15 tumors with TK over 80 pmol/mg/min responded (86%), while only 4 of the 30 tumors (13%) with TK below 80 pmol/mg/min responded (p less than 0.001). TK appears to be useful in predicting the responses to chemotherapy.

摘要

对乳腺癌的胞质溶胶进行雌激素受体(ER)和胸苷激酶(TK)活性检测。在137例原发性乳腺癌研究中,ER与TK之间无相关性。57例转移性乳腺癌的TK结果与后续激素治疗或化疗的反应或失败情况相关。TK不能预测12例患者对激素治疗的反应。在45例接受化疗的患者中,TK超过80 pmol/mg/min的15个肿瘤中有13个有反应(86%),而TK低于80 pmol/mg/min的30个肿瘤中只有4个有反应(13%)(p小于0.001)。TK似乎有助于预测化疗反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验